Angiotensin II Type 2 Receptor Blockade Amplifies the Early Signals of Cardiac Growth Response to Angiotensin II in Hypertrophied Hearts

Jozef Bartunek, MD, PhD; Ellen O. Weinberg, PhD; MinorI Tajima, MD, PhD; Susanne Rohrbach, BA; Beverly H. Lorell, MD

Background—We have previously shown that the acute molecular growth response of new protein synthesis and protein kinase C activation in response to angiotensin II (Ang II) is altered in left ventricular (LV) hypertrophy compared with normal hearts. We have also shown an upregulation of Ang II type 2 (AT2) receptors in hypertrophied hearts relative to controls. Activation of AT2 receptors is proposed to counteract growth effects of AT1 receptor in response to Ang II. Thus, we tested the hypothesis that in hypertrophied hearts, the AT2 receptor mediates inhibitory effects on the new cardiac protein synthesis in response to acute Ang II stimulation.

Methods and Results—Flaccid buffer-perfused adult normal and hypertrophied rat hearts were perfused with Ang II 10^-8 mol/L plus prazosin 10^-7 mol/L or Ang II plus the AT2 blocker PD 123319 5x10^-7 mol/L. New protein synthesis was measured by the rate of [3H]phenylalanine incorporation into the LV proteins. In normal hearts, Ang II (n=8) increased the rate of [3H]phenylalanine incorporation by 74±27% (P<0.05 versus no drug). Treatment with PD123319 (n=8) did not increase protein synthesis compared with Ang II alone (32±11% versus Ang II alone, P=NS). In hypertrophied hearts, Ang II alone (n=6) increased the rate of [3H]phenylalanine incorporation only by 23±13% (P=NS versus no drug). In contrast, treatment with PD123319 (n=7) induced a 76±21% increase in new LV protein synthesis compared with Ang II alone (P<0.05). AT2 receptor blockade in Ang II–stimulated hypertrophied hearts was associated with enhanced membrane protein kinase C translocation and reduced LV cGMP content.

Conclusions—These data support the hypothesis that in adult hypertrophied rat hearts, inhibition of cardiac AT2 receptors, which are upregulated in chronic LV hypertrophy, amplifies the immediate LV growth response to Ang II. This appears to be related to augmented Ang II–stimulated PKC activation and suppression of cGMP signaling. (Circulation. 1999;99:22-25.)

Key Words: angiotensin ▪ hypertrophy ▪ signal transduction

In neonatal cardiac myocytes1 and intact adult hearts,2,3 angiotensin (Ang) II stimulates early signals of the cardiac growth, such as new cardiac protein synthesis, independently of the load. This response depends on translocation of protein kinase C (PKC)-e from cytosol to membrane fraction and is blocked by the specific Ang II type 1 (AT1) receptor antagonist losartan.1,4-6 In contrast with neonatal myocytes, early signals of the cardiac growth response to Ang II in adult rat hearts do not involve the induction of proto-oncogenes, which occurs in response to load.1,4-8 We have also shown that the acute cardiac growth response of new cardiac protein synthesis and PKC translocation in response to Ang II is blunted in hypertrophied hearts with aortic stenosis relative to normal hearts.2,3 Recent observations suggest that this may be mediated by the Ang II type 2 (AT2) receptor. We8 and others10 have demonstrated an upregulation of LV AT2 receptors in hypertrophied hearts. Similar upregulation of AT2 receptors was reported in human failing myocardium.11,12 Several studies have proposed that downstream signaling related to the AT2 receptor differs strikingly from signaling of the AT1 receptor and involves kinin/cGMP signaling rather than the PKC pathway.13-17 Transgenic experiments suggest that the AT2 receptor signaling cascade has distinct biological roles compared with AT1 receptor–mediated signaling.18,19 Consistent with this hypothesis, recent studies in vascular smooth muscle cells20 and endothelial cells21 demonstrated that the AT2 receptor exerts antiproliferative effects counteracting the growth-promoting effects of the AT1 receptor. In contrast, the role of AT2 receptor–mediated signaling in cardiac growth of the intact adult heart is not known. Thus, in the present study, we tested the hypothesis that in hypertrophied hearts, the AT2 receptor mediates inhibitory effects on the new cardiac protein synthesis and PKC activation in response to acute Ang II stimulation.

Received July 31, 1998; revision received November 3, 1998; accepted November 5, 1998.
From the Cardiovascular Division, The Harvard Thrombolytic Laboratory, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.
Correspondence to Beverly H. Lorell, MD, Cardiovascular Division, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215.
E-mail blorell@bidmc.harvard.edu
© 1999 American Heart Association, Inc.
Circulation is available at http://www.circulationaha.org

22
Weight and Hemodynamics of Isolated Hypertrophied and Normal Hearts

<table>
<thead>
<tr>
<th></th>
<th>Normal Hearts</th>
<th>Hypertrophied Hearts</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No Drug (n=4)</td>
<td>Ang II (n=8)</td>
</tr>
<tr>
<td>Body weight, g</td>
<td>344±3</td>
<td>370±15</td>
</tr>
<tr>
<td>LV weight, g</td>
<td>0.85±0.03</td>
<td>0.89±0.03</td>
</tr>
<tr>
<td>LV/body weight, mg/g</td>
<td>2.46±0.09</td>
<td>2.39±0.05</td>
</tr>
<tr>
<td>Coronary flow, mL·min⁻¹·g⁻¹</td>
<td>23.3±2.1</td>
<td>20.9±0.9</td>
</tr>
</tbody>
</table>

Methods

Weanling male Wistar rats (75 to 90 g, Charles River Breeding Laboratories, Wilmington, Del) underwent ascending aortic stenosis as previously described (n=44).2,3,9 Age-matched animals served as a control group (n=45). At 7 to 9 weeks after the banding, the isolated flaccid hearts were perfused by modified Krebs-Henseleit buffer at 37°C as previously described.2,3,7-9 Measurements of protein synthesis, the buffer contained 0.05% albumin and a mixture of amino acids as previously described.2,3,8

To investigate the effects of AT₁ blockade on Ang II–induced new cardiac protein synthesis, normal and hypertrophied hearts were perfused with no drug (n=4), with Ang II 10⁻⁸ mol/L plus 10⁻⁷ mol/L prazosin (n=6 to 8), and with Ang II plus the selective AT₂ blocker PD123319 (Parke-Davis, 5×10⁻⁷ mol/L, n=6 or 7). The α₁-blocker prazosin was used to prevent any indirect stimulation of protein synthesis via activation of the postsynaptic sympathetic system.3,4 The dose of PD123319 was chosen on the basis of previous studies9,13,14 demonstrating a selective AT₂ receptor blockade in response to Ang II. After 60 minutes of perfusion, hearts were perfused for another 120 minutes with the same buffer, to which 0.5 mCi/L [³H]phenylalanine was added.2,3,8 As protein synthesis during the 120 minutes of perfusion was assumed to be linear,2,3,9,22 was calculated as follows: phenylalanine incorporation (mole·g protein⁻¹·h⁻¹) = phenylalanine (dpm·g protein⁻¹·h⁻¹) per gram in hypertrophied and normal hearts (Table).

Results

Characteristics of Hypertrophied and Normal Hearts

There was an 80% to 90% increase in LV weight in aortic stenosis versus normal hearts (Table). By study design, coronary flow was adjusted at baseline to achieve a similar coronary flow per gram in hypertrophied and normal hearts (Table).

Effects of AT₁ Blockade on Ang II–Induced Phenylalanine Incorporation

The rate of [³H]phenylalanine incorporation into proteins in the absence of drug was similar in normal and hypertrophied hearts (Figure 1). Corroborating our previous findings,2 Ang II–induced phenylalanine incorporation increased in normal hearts but did not in hypertrophied hearts. In normal hearts stimulated with Ang II, the rate of phenylalanine incorporation did not increase further during AT₁ receptor blockade. In contrast, in hypertrophied hearts stimulated with Ang II, phenylalanine incorporation was increased by AT₁ receptor blockade.

Effects of AT₂ Blockade on Ang II–Induced PKC-ε Translocation in Adult Rat Hearts

In normal and hypertrophied hearts with no drug, the membrane fraction of PKC composed 41.6±2.7% and 46.3±1.3% of total PKC content (P=NS). Normal hearts stimulated with Ang II demonstrated a significant increase in membrane fraction of PKC (24.9±8.6% versus no drug, P<0.05) that was not further modified by AT₂ blockade (25.5±5.8% versus no drug, Figure 2, left). In hypertrophied hearts, Ang II alone did not cause a significant increase in membrane translocation of PKC (8.8±4.1% versus no drug, Figure 2, right). Ang II induced a significant increase in rate of [³H]phenylalanine incorporation. In normal hearts, Ang II–induced cardiac protein synthesis did not significantly increase further during AT₂ blockade. In hypertrophied hearts (right), Ang II alone did not promote an increase in new LV protein synthesis compared with hearts perfused with no drug. In contrast, Ang II–stimulated LV protein synthesis was markedly amplified by selective AT₂ blockade in hypertrophied hearts.

Figure 1. LV protein synthesis assessed by [³H]phenylalanine incorporation in normal and hypertrophied hearts. In normal hearts (left), Ang II induced a significant increase in rate of [³H]phenylalanine incorporation. In normal hearts, Ang II–induced cardiac protein synthesis did not significantly increase further during AT₂ blockade. In hypertrophied hearts (right), Ang II alone did not promote an increase in new LV protein synthesis compared with hearts perfused with no drug. In contrast, Ang II–stimulated LV protein synthesis was markedly amplified by selective AT₂ blockade in hypertrophied hearts.
synthesis and PKC translocation. Thus, these data support the benefit of AT2 blockade. In contrast, in hypertrophied hearts, AT2 blockade amplified PKC translocation in hypertrophied hearts. In normal hearts with a predominance of LV AT1 receptors,9–10 Ang II–induced new cardiac protein synthesis did not increase further during selective AT2 blockade. In contrast, in hypertrophied hearts, AT2 receptor blockade increased Ang II–induced LV protein synthesis and PKC translocation. Thus, these data support the hypothesis that AT2 receptor activation mediates inhibitory effects on acute growth response to Ang II in adult intact hearts with LV hypertrophy.

Recent studies suggested that AT2 receptor–related biological effects are due to activation of kinins and intracellular cGMP signaling.13–17 Our data corroborate these findings by demonstrating that AT2 blockade decreases in LV cGMP content in intact hearts stimulated by Ang II. In addition, AT2 blockade amplified PKC translocation in hypertrophied hearts stimulated with Ang II. Of note, this effect was absent in normal hearts. The presence of cross talk between PKC translocation and selective AT2 blockade in hypertrophied hearts with upregulated AT2 receptors9–12 is consistent with a report of Yamada et al.,24 who demonstrated that AT2 receptor activation inhibits mitogen-activated protein kinase. In addition, several authors proposed that AT2 receptor activation may enhance apoptotic cell death.17,24 These hypotheses merit future studies in the present aortic stenosis model of chronic LV hypertrophy and failure.

The present study has several limitations. First, the isolated-perfused heart model does not allow investigation of later components of the growth response, namely myocyte hypertrophy. Second, it does not distinguish whether changes in protein synthesis or PKC translocation are localized predominantly to cardiac myocytes or also to matrix cells that express Ang II receptors.

In summary, the present study shows that AT2 receptor blockade amplifies new cardiac protein synthesis in response to Ang II in hypertrophied hearts. This appears to be related to both AT1 and AT2 receptor activation. The beneficial or detrimental effects of chronic AT2 receptor blockade on hypertrophic remodeling and the transition to failure in pressure-overload hypertrophy remain to be investigated.

Acknowledgments
This study was supported in part by National Heart, Lung, and Blood Institute grant HL-38189 (Drs Lorette and Weinberg) and by fellowship award F05 TW075261-01 from the Fogarty International Center, NIH (Dr Bartunek).

References


Angiotensin II Type 2 Receptor Blockade Amplifies the Early Signals of Cardiac Growth Response to Angiotensin II in Hypertrophied Hearts

Jozef Bartunek, Ellen O. Weinberg, Minori Tajima, Susanne Rohrbach and Beverly H. Lorell

_Circulation_. 1999;99:22-25
doi: 10.1161/01.CIR.99.1.22

_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1999 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/99/1/22